A 2018 study by the Working Group for the MDS Molecular Prognostic Committee on 339 MDS patients found that 55% of those with a complex karyotype had TP53 mutations, a greater determinant of poorer overall survival than either monosomy or a complex karyotype. This evidence concerns the gene TP53 and myelodysplastic syndrome.